Evaxion Out-licenses Vaccine Candidate EVX-B3 To Merck & Co.

TechBio company Evaxion A/S (EVAX) out-licensed its preclinical vaccine candidate EVX-B3 to Merck & Co. (MSD) for an upfront payment of $7.5 million, with potential development, regulatory, and sales milestones of up to $592 million, plus royalties; MSD will bear all future development costs. This deal, validating Evaxion's AI-Immunology platform and targeting a serious global medical issue, extends Evaxion's cash runway into H1 2027. Separately, MSD extended its evaluation period for another candidate, EVX-B2, until H1 2026, which could yield an additional $2.5 million upfront and similar milestone payments if the option is exercised.

Analysis

Evaxion A/S (EVAX) has secured a significant partnership by out-licensing its preclinical vaccine candidate, EVX-B3, to Merck & Co. (MRK). The agreement provides Evaxion with an immediate $7.5 million cash payment, which extends its operational cash runway into the first half of 2027, thereby mitigating near-term financing risks. This deal represents a critical validation of Evaxion's proprietary AI-Immunology platform by a major pharmaceutical firm. Beyond the upfront payment, Evaxion is eligible for up to $592 million in development, regulatory, and sales milestones, plus royalties on net sales, while Merck will absorb all future development costs for EVX-B3. This arrangement de-risks the asset's development path for Evaxion. Furthermore, the collaboration includes a second candidate, EVX-B2, for which Merck has extended its evaluation period to the first half of 2026. A positive decision on EVX-B2 could bring an additional $2.5 million upfront and a similar milestone structure, representing another potential value inflection point for Evaxion.

Key Decisions for Investors

• The out-licensing deal provides significant validation for Evaxion's AI-Immunology platform and extends its cash runway to H1 2027, substantially de-risking the company's near-term investment profile and potentially justifying a valuation re-rating.
• Investors should monitor future progress on the Merck-led EVX-B3 development, as the realization of up to $592 million in milestones is the key long-term value driver, while also tracking the H1 2026 decision on the EVX-B2 candidate as the next major potential catalyst.
• While positive, the majority of the deal's economic value remains contingent on long-term, high-risk clinical and regulatory success, so positions should be sized to reflect the preclinical nature of the assets involved.
• For investors in Merck, this transaction represents a minor, early-stage pipeline addition consistent with its strategy of leveraging external innovation and is not material to its overall financial outlook.